We are aware of ongoing supply issues with some hormone replacement therapy (HRT) preparations due to a range of issues including manufacturing issues, regulatory issues and problems accessing the raw pharmaceutical ingredient as well as commercial decisions made by some companies to divest these products.
We have been working closely with all suppliers of HRT preparations to maintain overall supply to patients. We have shared relevant information about the supply situation and availability of HRT products with the National Health Service and are having discussions with organisations such as the Royal College of Obstetricians and Gynaecologists, the Faculty of Sexual and Reproductive Healthcare and the British Menopausal Society.
We continue to work with all stakeholders to ensure relevant information about the HRT products affected by supply issues and the products that remain available is shared with the NHS on a regular basis.
We anticipate the supply situation will improve from February 2020.